Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

0.9832 -0.0143 (-1.43%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fate Therapeutics, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Beyond Meat, Canoo, Veru And More: 12 Short Squeeze Candidates To Watch ↗
One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky has just released a... 
Via Benzinga
News headline image
Despite Durability Questions, BMO Upgraded This Natural-Killer Cell Therapy Oncology Stock ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 12, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Expert Ratings for Fate Therapeutics ↗
Within the last quarter, Fate Therapeutics (NASDAQ:FATE) has observed the following analyst ratings: 
Via Benzinga
News headline image
Recap: Fate Therapeutics Q1 Earnings ↗
Fate Therapeutics (NASDAQ:FATE) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2022 ↗
Upgrades 
Via Benzinga
News headline image
7 Small-Cap Stocks to Buy in July 2022 ↗
These are the best small-cap stocks to buy for July 2022. ARCH, AVUV, CEIX, COUR, DVAX, FATE, and TENB can make great investments. 
Via InvestorPlace
News headline image
Earnings Scheduled For February 28, 2022 ↗
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
News headline image
Will Another Enlivex Innovation Break The Glass Ceiling For Solid Tumor Treatments? ↗
Cell therapy — the use of stem cells and various engineered immune cells to target difficult-to-treat diseases like cancer and autoimmune conditions — has arguably been one of the big breakthroughs in... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022 ↗
 
Via Benzinga
News headline image
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Fate Therapeutics ↗
Within the last quarter, Fate Therapeutics (NASDAQ:FATE) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total... 
Via Benzinga
News headline image
Fate Therapeutics: Q4 Earnings Insights ↗
Fate Therapeutics (NASDAQ:FATE) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
News headline image
Fate Therapeutics's Earnings: A Preview ↗
Fate Therapeutics (NASDAQ:FATE) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
News headline image
Earnings Outlook For Fate Therapeutics ↗
Fate Therapeutics (NASDAQ:FATE) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
News headline image
2 Natural-Killer Cell Therapy Oncology Companies Investors Should Watch ↗
Natural-killer cell therapy is one of the most recent paradigms in cancer treatment, and two prominent companies working on this new technology are Fate Therapeutics Inc (NASDAQ: FATE) and Century... 
Via Benzinga
News headline image
Benzinga Asks: Which ARK Fund Would You Rather Buy And Hold For 5 Years? ↗
One of the best-known and well-covered ETF companies over the past five years has been ARK Invest, led by Cathie Wood. With t... 
Via Benzinga
News headline image
Here's How Much $100 Invested In Fate Therapeutics 5 Years Ago Would Be Worth Today ↗
Fate Therapeutics (NASDAQ:FATE) has outperformed the market over the past 5 years by 64.83% on an annualized basis. Buying $100 In FATE: 5 years ago, an investor could have... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021 ↗
Upgrades B of A Securities upgraded the previous rating for ONE Gas Inc (NYSE: 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Wednesday ↗
Barclays boosted the price target on Sysco Corporation (NYSE: 
Via Benzinga
News headline image
The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Vaccitech To Buy Avidea For $40M Vaccitech plc (NASDAQ: VACC) announced that... 
Via Benzinga
News headline image
Fate Therapeutics Showcases Interim Data From FT596 Cell Program In Lymphoma ↗
Fate Therapeutics Inc (NASDAQ: FATE) showcased interim Phase 1 data from its FT596 program for patients with relapsed / refractory B-cell lymphoma (BCL) at the... 
Via Benzinga
News headline image
Hedge Funds Are Selling Vontier Corporation ↗
Vontier Corporation investors should pay attention to a decrease in activity from the world’s largest hedge funds recently. Vontier Corporation was in 31 hedge funds’ portfolios at the end of... 
Via Talk Markets
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021 ↗
Upgrades For CarMax Inc (NYSE: 
Via Benzinga
News headline image
Cathie Wood Likes Fate Therapeutics, Should You? ↗
The biotech has an interesting pipeline, but it's all early stage products. 
Via The Motley Fool
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2021 ↗
Upgrades JP Morgan upgraded the previous rating for New Relic Inc (NYSE: 
Via Benzinga
News headline image
Fate Therapeutics, inc (FATE) Q3 2021 Earnings Call Transcript ↗
FATE earnings call for the period ending October 31, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.